How profitable is Prothena Corporation plc (PRTA)?

In FY 2025 (10-K), PRTA converted $9.7M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / PRTA / financials

BLSM (42) CRMD (59) KMDA (46) ASMB (16) ⌘ Pro Terminal →

Prothena Corporation plc (PRTA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.29 -2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.24

Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $434.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRTA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $8.29 (-2.12% 1D, market cap $434.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #945 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRTA compare to BLSM and CRMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRTA?

▼

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.24 (-0.57%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY PRTA SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (26% of score)

20D Institutional Volume Accumulation (±11% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.36+1.7% Next Q

Q2 (-2Q)

Grade E$8.50+3.6% Next Q

Q3 (-1Q)

Grade E$8.81-5.9% Next Q

Current

Grade E$8.29-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRTA currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.73) and Max Pain ($8.70) forces dealer call-delta covering toward $12.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PRTA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $91.4M

FY24

Rev $135.2M

FY25

Rev $9.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$9.7M	52%	-80%	-$244.1M	-$163.6M	-45%
FY 2024	$135.2M	52%	-80%	-$122.3M	-$150.1M	-45%
FY 2023	$91.4M	52%	-80%	-$147.0M	-$133.9M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)

✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.17%▼ DESCENDING CHANNEL

2026-11-03O $8.88H $8.88L $8.29C $8.29VOL 452.3K

RES: $9.21SUP: $7.71SMA50: $8.73SMA200: $9.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRTA Butterfly Map → + Track PRTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)

Health Care Rank #945 of 1016 ⚔️ BLSM vs PRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRTA vs. BLSM, CRMD, KMDA, ASMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #945 by composite RQD confidence (23/100, grade E) and #465 by equity capitalization ($434.8M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PRTA at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRTA ACTIVE Prothena Corporation plc	E	23/100	—	—	-35.0%	-2.12%	$434.8M	Benchmark Subject
BLSM BlossomHill Therapeutics Inc.	D-	42/100	—	—	—	-9.67%	$437.0M	/blsm-vs-prta →
CRMD CorMedix Inc.	C-	59/100	3.7x	88.5%	45.5%	-5.36%	$443.9M	/crmd-vs-prta →
KMDA Kamada Ltd.	D	46/100	—	—	—	-4.42%	$444.4M	/kmda-vs-prta →
ASMB Assembly Biosciences Inc.	E	16/100	—	—	-6.5%	-3.08%	$409.9M	/asmb-vs-prta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.7M	-$244.1M	-$163.6M	-$163.6M	$326.8M	—
FY2024 (FY)	2024-12-31	$135.2M	-$122.3M	-$150.1M	-$150.1M	$547.1M	—
FY2023 (FY)	2023-12-31	$91.4M	-$147.0M	-$133.9M	-$133.9M	—	—

3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRTA compare to BLSM and CRMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRTA?

Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRTA last traded at $8.29 (-2.12% on volume of 462,524 shares), positioning the stock -5.04% below its 50-day simple moving average ($8.73) and -10.18% below its 200-day simple moving average ($9.23). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 13.8% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($7.38 to $9.20).

Direct Sub-Reports: PRTA RQD Cockpit PRTA 12M Forecast PRTA Earnings & Move PRTA Dividends & DRIP PRTA Insiders & 13F PRTA Whale Options PRTA Profit Sankey PRTA News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRTA — Prothena Corporation plc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:16Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

PRTA scores 26 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 5 out of 20, reflecting ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on capital or free cash flow, so any valuation case must rest on future cash generation rather than present earnings. The Whale 13F Flow pillar scores 9 out of 20, indicating institutional accumulation and options positioning that are weaker than the top of the scale. The Insider Conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest of the five pillars, which signals limited insider-side confidence in the source data. The Macro Regime Fit pillar scores 7 out of 20, with a beta of 1.0 and sector sensitivity that offers no defensive cushion. The Forensic Balance Sheet pillar scores 2 out of 20, with an Altman Z of 0.2, a Piotroski F of 2 out of 9, and Debt/Equity of 0.5, placing financial-distress risk at the center of the thesis. Taken together, the upside drivers are limited to a cash balance and a potential recovery in operating trajectory, while the tradeoffs are negative operating margins, distress-range forensic scores, and a rating that flags avoidance.

2. Business Model, Unit Margins & SEC Financial Trajectory

.5B. Reported revenue was $9.7M in FY 2025, $135.2M in FY 2024, and $91.4M in FY 2023, indicating material year-to-year variation. — for further detail on how the company monetizes its activities.

Per the market data, operating margin and net margin are both -60%, and gross margin is 0%. ROIC is -35% and the Altman Z-Score is 0.2, with a Piotroski F-Score of 2 out of 9 and Debt/Equity of 0.5. Cash declined from $471.4M in FY 2024 to $307.5M in FY 2025 while free cash flow remained negative in each reported period.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Cash of $307.5M at FY 2025 provides a balance-sheet buffer while the stock trades near the low end of its $7.73 - $11.8 52-week range. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $7.73 – $11.80 52-week range.
🐻 Primary Bear Case: With ROIC at -35%, FCF yield at 0%, and an Altman Z of 0.2, the RQD rating flags forensic distress risk and recommends avoidance. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRTA carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: What is the debt position, since debt is reported as N/A in every period while Debt/Equity is cited at 0.5?
Key Question #2: What is the cash runway implied by $307.5M of cash against FY 2025 free cash flow of -$163.6M?
Key Question #3: What is the basis and timing of the partnership strategy referenced in news coverage, and how would it affect revenue?

PRTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prothena Corporation plc (PRTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRTA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 23h ago

Prothena to Report Third Quarter 2026 Financial Results on November 5

www.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Prothena's Partnership Strategy: Growth Driver or Limitation?

Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

PRTA Q3'26 Earnings: EPS estimate is (0.23) USD

TradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(PRTA) and the Role of Price-Sensitive Allocations

Stock Traders Daily report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Aspen Neuroscience (ASPE) Stock Price, News & Analysis

Stock Titan report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Prothena Corporation Public Limited Company Terminates PRX019 Global License Agreement With Bristol Myers Squibb

www.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CLYM Stock Price and Chart — NASDAQ:CLYM

TradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRTA Bull vs. Bear Conversation Board — What's Your Call at $8.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRTA 🐻 33% BEARISH CONVICTION

QU QuantViper Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $10.16 (+20.0%)

📌 Pinned Debate

Cash of $307.5M at FY 2025 provides a balance-sheet buffer while the stock trades near the low end of its $7.73 - $11.8 52-week range.

Long PRTA at $8.47 targeting $10.16. Cash of $307.5M at FY 2025 provides a balance-sheet buffer while the stock trades near the low end of its $7.73 - $11.8 52-week range.. Institutional whale score is 6/20 and the risk/reward vs. the $7.73 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 6/20 institutional whale-flow stock at $8.47 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH 🎯 Target: $7.11 (-16.1%)

Spot @ $8.47

With ROIC at -35%, FCF yield at 0%, and an Altman Z of 0.2, the RQD rating flags forensic distress risk and recommends avoidance.

Sitting on the sidelines or leaning short PRTA above $8.47. With ROIC at -35%, FCF yield at 0%, and an Altman Z of 0.2, the RQD rating flags forensic distress risk and recommends avoidance.. Until Fundamental Cash Engine (5/20) and FCF yield (0.0%) inflect higher, upside is capped near $11.80.